| Authors: |
Lee HC; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA., Becnel MR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA., Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA., Pasvolsky O; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA., Murga A; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA., Johnson RJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA., Thomas SK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA., Bashir Q; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Qazilbash MH; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Steiner R; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Iyer SP; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA., Weber DM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA., Patel KK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA., Kaufman GP; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA., Manasanch EE; GlaxoSmithKline, Philadelphia, Pennsylvania, USA., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
